# Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

> **NCT03633526** · PHASE3 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 18 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-659/TEZ/IVA
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT03633526
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-03
- **Primary completion:** 2019-01-18
- **Final completion:** 2019-01-18
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study discontinued after Part A due to Sponsor's discretion.
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03633526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03633526, "Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03633526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*